Anthropic begins in-house drug discovery efforts

The author argues that frontier AI labs are positioning themselves to become next-generation biotech platforms rather than mere software vendors, driven by closed-loop experimentation and internal drug discovery pipelines. Anthropic and OpenAI are actively acquiring biotech firms, establishing in-house wet labs, and building automated research infrastructure. Meanwhile, pharmaceutical companies such as Eli Lilly are developing competing proprietary AI discovery platforms to protect their market position. Open article →